- $365.03m
- $371.80m
- $79.91m
- 46
- 13
- 94
- 50
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 45.55 | ||
| Price to Tang. Book | 45.55 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -27.26% | ||
| Return on Equity | -189.35% | ||
| Operating Margin | -27.12% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 41.14 | 45.18 | 45.52 | 65.42 | 79.91 | 93.64 | 104.72 | 16.67% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
Directors
- Frank Fischer CHM (79)
- Michael Favet PRE (51)
- Rebecca Kuhn CFO (60)
- Mark Saxton VPR (55)
- Chi Nguyen VPR (44)
- Isabella Abati VPR (61)
- Cairn Seale VPR (50)
- Dylan St. John VPR (43)
- Irene Thomas VPR (52)
- Irina Ridley GCN (75)
- Martha Morrell OTH (64)
- Lisa Andrade DRC
- Vince Burgess DRC
- Greg Garfield IND (58)
- Rakhi Kumar IND (41)
- Joseph Lacob IND (64)
- Renee Ryan IND (52)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 19th, 1997
- Public Since
- April 22nd, 2021
- No. of Shareholders
- 145
- No. of Employees
- 184
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 32,752,746
- Address
- 455 N. Bernardo Avenue, MOUNTAIN VIEW, 94043
- Web
- https://www.neuropace.com/
- Phone
- +1 6502372700
- Auditors
- PricewaterhouseCoopers LLP (USA)
Upcoming Events for NPCE
Q1 2025 Neuropace Inc Earnings Call
Neuropace Inc Annual Shareholders Meeting
Neuropace Inc Annual Shareholders Meeting
Q2 2025 Neuropace Inc Earnings Release
Similar to NPCE
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
AtriCure
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
FAQ
What is the Neuropace share price?
As of Today at 22:14 UTC, shares in Neuropace are trading at $11.15. This share price information is delayed by 15 minutes.
How has the Neuropace share price performed this year?
Shares in Neuropace last closed at $11.15 and the price had moved by -14.2% over the past 365 days. In terms of relative price strength the Neuropace share price has underperformed the S&P500 Index by -20.81% over the past year.
What are the analyst and broker recommendations for Neuropace?
The overall consensus recommendation for Neuropace is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Neuropace dividend yield?
Neuropace does not currently pay a dividend.
Does Neuropace pay a dividend?
Neuropace does not currently pay a dividend.
When does Neuropace next pay dividends?
Neuropace does not currently pay a dividend.
How do I buy Neuropace shares?
To buy shares in Neuropace you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Neuropace?
As of the previous close price of $11.15, shares in Neuropace had a market capitalisation of $365.03m.
Where are Neuropace shares listed?
Here are the trading details for Neuropace:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: NPCE
What kind of share is Neuropace?
Based on an overall assessment of its quality, value and momentum Neuropace is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Neuropace share price forecast for 2025?
The analyst consensus target price for shares in Neuropace is $16.86. That is 51.28% above the last closing price of $11.15.
Analysts covering Neuropace currently have a consensus Earnings Per Share (EPS) forecast of -$0.85 for the next financial year.
Find out moreWhat is the trend in the Neuropace share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Neuropace. Over the past six months, its share price has outperformed the S&P500 Index by +84.99%.
As of the last closing price of $11.15, shares in Neuropace were trading +15.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Neuropace PE Ratio?
The Neuropace PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $11.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Neuropace?
Neuropace's management team is headed by:
- Frank Fischer - CHM
- Michael Favet - PRE
- Rebecca Kuhn - CFO
- Mark Saxton - VPR
- Chi Nguyen - VPR
- Isabella Abati - VPR
- Cairn Seale - VPR
- Dylan St. John - VPR
- Irene Thomas - VPR
- Irina Ridley - GCN
- Martha Morrell - OTH
- Lisa Andrade - DRC
- Vince Burgess - DRC
- Greg Garfield - IND
- Rakhi Kumar - IND
- Joseph Lacob - IND
- Renee Ryan - IND